BACKGROUND: The effect of herpes simplex virus type 2 (HSV-2) suppression on human immunodeficiency virus type 1 (HIV-1) RNA in the context of prevention of mother-to-child transmission (PMTCT) interventions is unknown. METHODS:Between April 2008 and August 2010, we conducted a randomized, double-blind trial of twice daily 500 mg valacyclovir or placebo beginning at 34 weeks gestation in 148 HIV-1/HSV-2 coinfected pregnant Kenyan women ineligible for highly active antiretroviral therapy (CD4 > 250 cells/mm(3)). Women received zidovudine and single dose nevirapine for PMTCT and were followed until 12 months postpartum. RESULTS: Mean baseline plasma HIV-1 RNA was 3.88 log(10) copies/mL. Mean plasma HIV-1 was lower during pregnancy (-.56 log(10) copies/mL; 95% confidence interval [CI], -.77 to -.34) and after 6 weeks postpartum (-.51 log(10) copies/mL; 95% CI, -.73 to -.30) in the valacyclovir arm than the placebo arm. Valacyclovir reduced breast milk HIV-1 RNA detection at 6 and 14 weeks postpartum compared with placebo (30% lower, P = .04; 46% lower, P = .01, respectively), but not after 14 weeks. Cervical HIV-1 RNA detection was similar between arms (P = .91). CONCLUSIONS:Valacyclovir significantly decreased early breast milk and plasma HIV-1 RNA among women receiving PMTCT. CLINICAL TRIALS REGISTRATION: NCT00530777.
RCT Entities:
BACKGROUND: The effect of herpes simplex virus type 2 (HSV-2) suppression on human immunodeficiency virus type 1 (HIV-1) RNA in the context of prevention of mother-to-child transmission (PMTCT) interventions is unknown. METHODS: Between April 2008 and August 2010, we conducted a randomized, double-blind trial of twice daily 500 mg valacyclovir or placebo beginning at 34 weeks gestation in 148 HIV-1/HSV-2 coinfected pregnant Kenyan women ineligible for highly active antiretroviral therapy (CD4 > 250 cells/mm(3)). Women received zidovudine and single dose nevirapine for PMTCT and were followed until 12 months postpartum. RESULTS: Mean baseline plasma HIV-1 RNA was 3.88 log(10) copies/mL. Mean plasma HIV-1 was lower during pregnancy (-.56 log(10) copies/mL; 95% confidence interval [CI], -.77 to -.34) and after 6 weeks postpartum (-.51 log(10) copies/mL; 95% CI, -.73 to -.30) in the valacyclovir arm than the placebo arm. Valacyclovir reduced breast milk HIV-1 RNA detection at 6 and 14 weeks postpartum compared with placebo (30% lower, P = .04; 46% lower, P = .01, respectively), but not after 14 weeks. Cervical HIV-1 RNA detection was similar between arms (P = .91). CONCLUSIONS:Valacyclovir significantly decreased early breast milk and plasma HIV-1 RNA among women receiving PMTCT. CLINICAL TRIALS REGISTRATION: NCT00530777.
Authors: Christine M Rousseau; Ruth W Nduati; Barbra A Richardson; Grace C John-Stewart; Dorothy A Mbori-Ngacha; Joan K Kreiss; Julie Overbaugh Journal: J Infect Dis Date: 2004-10-07 Impact factor: 5.226
Authors: Liesbeth Jm Bollen; Sara J Whitehead; Philip A Mock; Wanna Leelawiwat; Suvanna Asavapiriyanont; Amphan Chalermchockchareonkit; Nirun Vanprapar; Tawee Chotpitayasunondh; Janet M McNicholl; Jordan W Tappero; Nathan Shaffer; Rutt Chuachoowong Journal: AIDS Date: 2008-06-19 Impact factor: 4.177
Authors: A C Collier; S Bozzette; R W Coombs; D M Causey; D A Schoenfeld; S A Spector; C B Pettinelli; G Davies; D D Richman; J M Leedom Journal: N Engl J Med Date: 1990-10-11 Impact factor: 91.245
Authors: Ronald H Gray; X Li; Maria J Wawer; David Serwadda; Nelson K Sewankambo; Fred Wabwire-Mangen; Tom Lutalo; Noah Kiwanuka; Godfrey Kigozi; Fred Nalugoda; Mary P Meehan; Merlin Robb; Thomas C Quinn Journal: J Infect Dis Date: 2004-03-15 Impact factor: 5.226
Authors: Christophe Vanpouille; Andrea Lisco; Andrea Introini; Jean-Charles Grivel; Arshi Munawwar; Melanie Merbah; Raymond F Schinazi; Marco Derudas; Christopher McGuigan; Jan Balzarini; Leonid Margolis Journal: Antimicrob Agents Chemother Date: 2012-02-06 Impact factor: 5.191
Authors: Alison L Drake; Suzanne K Wilson; John Kinuthia; Alison C Roxby; Daniel Matemo; Carey Farquhar; Deepa Rao Journal: Glob Public Health Date: 2015-02-03
Authors: Alison C Roxby; Daniel Matemo; Alison L Drake; John Kinuthia; Grace C John-Stewart; Francisca Ongecha-Owuor; James Kiarie; Carey Farquhar Journal: AIDS Patient Care STDS Date: 2013-01 Impact factor: 5.078
Authors: Christophe Vanpouille; Andrea Lisco; Jean-Charles Grivel; Leda C Bassit; Robert C Kauffman; Jorge Sanchez; Raymond F Schinazi; Michael M Lederman; Benigno Rodriguez; Leonid Margolis Journal: Clin Infect Dis Date: 2015-03-03 Impact factor: 9.079
Authors: Sten H Vermund; José A Tique; Holly M Cassell; Megan E Pask; Philip J Ciampa; Carolyn M Audet Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731
Authors: Alison C Roxby; Amy Y Liu; Alison L Drake; James N Kiarie; Barbra Richardson; Barbara L Lohman-Payne; Grace C John-Stewart; Anna Wald; Stephen De Rosa; Carey Farquhar Journal: AIDS Res Hum Retroviruses Date: 2012-09-04 Impact factor: 2.205